CDXS News and Press, Codexis Inc. From 06/10/21

Codexis (CDXS) has expanded its strategic collaboration and license agreement with Takeda Pharmaceutical (TAK) for the research and development of an additional gene therapy for a lysosomal storage disorder.This brings the total number of programs under the agreement to four. Under the terms ...

REDWOOD CITY, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, today announced the expansion of its strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (“Taked...

REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will participate in three upcoming virtual investment conferences. The UBS Global Healthcare Virtual Conference – May 24, 20...

"If you own the turbo-charged growth stocks... you either need to steel yourself for the pain or cut your losses on the next sharp move up, because we're in a new market that’s very different from last year," Jim Cramer said in the latest episode of Mad Money. "What worked in 2020 hasn...

A healthy gut can help improve everything from your emotional state of mind to your immune system. In fact, according to Euromonitor International, “about one-quarter of consumers globally suffer from lower digestive health issues. In half of those cases, consumers claim that this ha...

The following slide deck was published by Codexis, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Codexis, Inc. 2021 Q1 - Results - Earnings Call Presentation

Codexis (CDXS): Q1 GAAP EPS of -$0.14 beats by $0.07.Revenue of $18.03M (+22.9% Y/Y) beats by $3.61M.Codexis reiterates its previously issued financial guidance for 2021, as follows:Total revenues are expected to be in the range of $82 million to $85 millionProduct revenues are expected to be...

Total Revenue up 23% and Product Revenue Doubles Year over Year REDWOOD CITY, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced financial results for the first quarter...

REDWOOD CITY, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2021 on Thursday, May 6, 2021, following the close of market. Codexis management wil...

Piper Sandler paints an upbeat outlook for the synthetic biology (SynBio) space as the firm initiates coverage on Codexis (CDXS) and Twist Biosciences (TWST).Twist Bioscience and Codexis in focus as Piper Sandler sizes up synthetic biologyThe analyst Steven Mah predict the global market for s...